Illumina, Inc. is an American company. Incorporated on April 1, 1998, Illumina develops, manufactures, and markets integrated systems for the analysis of genetic variation and biological function. The company provides a line of products and services that serves the sequencing, genotyping and gene expression, and proteomics markets. Its headquarters are located in San Diego, California.
| Revenue (TTM) | $4.39B |
| Gross Profit (TTM) | $3.00B |
| EBITDA | $1.16B |
| Operating Margin | 18.30% |
| Return on Equity | 33.80% |
| Return on Assets | 8.68% |
| Revenue/Share (TTM) | $28.62 |
| Book Value | $17.61 |
| Price-to-Book | 10.71 |
| Price-to-Sales (TTM) | 6.65 |
| EV/Revenue | 6.84 |
| EV/EBITDA | 21.00 |
| Quarterly Earnings Growth (YoY) | 6.10% |
| Quarterly Revenue Growth (YoY) | 4.80% |
| Shares Outstanding | $151.30M |
| Float | $148.03M |
| % Insiders | 0.20% |
| % Institutions | 107.12% |
Volatility is currently contracting
Get a deeper insight into the potential performance of Illumina (ILMN) for the quarter ended June 2026 by going beyond Wall Street's top-and-bottom-line estimates and examining the estimates for some of its key metrics.
Investors with an interest in Medical - Biomedical and Genetics stocks have likely encountered both Exelixis (EXEL) and Illumina (ILMN). But which of these two stocks is more attractive to value investors?
CHICAGO--(BUSINESS WIRE)---- $ILMN #AI--Fishbone Advisors, a capital markets intelligence firm, today released a new report showing that healthcare's AI narrative has a credibility problem with institutional investors. In every healthcare subsector, roughly half to two-thirds of investors (48% to 67%) agree that management overemphasizes AI relative to its actual financial contribution, the most consistent finding in “Hallucinating Value: Healthcare's AI Narrative.” The findings come from the Fishbone Health.
Genomics is reshaping healthcare, and these three stocks - MYGN, SANA and WVE - stand out as rapid advances in personalized medicine and synthetic biology continue to transform the industry.
Partners will use unprecedented data scale to advance more precise medicines to approval SAN DIEGO, July 16, 2026 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) today announced that the Billion Cell Atlas alliance has added three new member companies, including AI-native drug developer Formation Bio. As leaders in AI-driven drug discovery, design, and development, alliance members will use the unprecedented scale of Illumina's genome-wide perturbation data as infrastructure for the next generation of therapeutics.
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
SAN DIEGO, July 9, 2026 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) announced today that it will issue results for the second quarter 2026 following the close of market on Thursday, July 30, 2026. On the same day, at 1:30 pm Pacific Time (4:30 pm Eastern Time) Jacob Thaysen, PhD, Chief Executive Officer, and Ankur Dhingra, Chief Financial Officer, will host a conference call with analysts, investors, and other interested parties to discuss financial and operating results.
Biotechnology stocks like Illumina, Eli Lilly and Exelixis have quietly turned into the new market leaders.
Does Illumina (ILMN) have what it takes to be a top stock pick for momentum investors? Let's find out.
ILMN stock's 43.7% 2026 rally is fueled by strong sequencing demand, NovaSeq X momentum and progress toward higher growth and profitability.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on ILMN and any ticker you trade — then tracks every position and per-strategy win rate.
